Kenvue earnings top estimates in J&J spinoff's first quarterly report since IPO

  • 📰 CNBC
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 72%

United States News News

United States United States Latest News,United States United States Headlines

J&J still owns a 90% stake in Kenvue, meaning it can generally control the direction of the consumer health spinoff’s business for the time being.

Kenvue, formerly J&J's consumer health division, holds a wealth of widely known brands such as Band-Aid, Tylenol, Listerine, Neutrogena, Aveeno and J&J's namesake baby powder.

Shares of Kenvue were flat in premarket trading Thursday. After a strong debut on the public market in May, the stock has struggled as investorshow much growth the company can deliver with its iconic brands as consumers pull back on spending. It reported a net income of $430 million, or 23 cents per share, compared with $604 million, or 35 cents per share, a year earlier. Excluding certain items, the company's adjusted earnings were 32 cents a share.

In April following its IPO, Kenvue said it expects annual sales growth through 2025 to be about 3% to 4% globally.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in US

United States United States Latest News, United States United States Headlines